---

AIDS Research Volume 10, Number 3 May/June 1995

Grants

NIDA Encourages More AIDS-Related Research

In its role as one of the leading AIDS research agencies at the National Institutes of Health, NIDA is strongly urging researchers to consider the relevance of their research to the issues around HIV/AIDS and to apply for NIDA support. Below are brief descriptions of all of NIDA's AIDS-related program announcements. Collectively, these provide an overview of the broad range of opportunities available in drug-abuse-related AIDS research.

Deadlines for AIDS-related grant applications are January 2, May 1, and September 1 of each year. Copies of program announcements and additional information can be obtained from NIDA's Grants Management Branch at (301) 443-6710. The Internet address is: gfleming@aoada.ssw.dhhs.gov

HIV Risk Behaviors, Determinants, and Consequences (PA-95-057)

This announcement calls for research on the social and other environmental factors that influence HIV risk behaviors of drug users and their sexual partners. Populations of interest include injecting drug users and their sexual partners and noninjecting drug users whose HIV risk behaviors may be related to their drug use.

For more information, contact Dr. Richard Needle, NIDA, 6001 Executive Blvd, Bethesda, Maryland 20892 , (301) 443-6720. Internet: rneedle@aoada.ssw.dhhs.gov

HIV Disease Progression in Drug Users (PA-95-026)

To assist in HIV prevention and treatment efforts, NIDA is seeking research on biological and behavioral factors influencing HIV disease progression among drug users. Proposals will be welcomed that increase understanding of viral, host, and environmental factors and their role in vulnerability and resistance to infection and rates of disease progression.

For further information, contact Katherine Davenny, 6001 Executive Blvd, Bethesda, Maryland 20892 , (301) 443-1801. Internet: kdavenny@aoada.ssw.dhhs.gov

Prevention of Relapse to High-Risk Behaviors (PA-95-030)

NIDA and the National Institute of Mental Health are calling for research that will help identify ways to prevent relapse to behaviors such as unsafe sexual conduct and sharing of drug-injection equipment that place people at high risk for HIV infection.

For further information, contact Dr. Steven Gust, NIDA, 6001 Executive Blvd, Bethesda, Maryland 20892 , (301) 443-6480. Internet: sgust@aoada2.ssw.dhhs.gov

AIDS, Drug Abuse, and Neurobiology (PA-95-005)

Drugs of abuse may weaken the immune systems of drug-abusing AIDS patients and put them at higher risk of contracting diseases such as tuberculosis that are now recognized as being associated with AIDS. Such drugs may initiate or advance the development of dementia as it relates to HIV. NIDA invites neuroscientists, endocrinologists, immunologists, chemists, molecular biologists, and others to submit proposals to conduct research on how drug abuse affects AIDS-related diseases.

For further information, contact Dr. Charles W. Sharp, NIDA, 6001 Executive Blvd, Bethesda, Maryland 20892 , (301) 443-1887. Internet:csharp@aoada.ssw.dhhs.gov

Drug Abuse Health Services Research and HIV/AIDS (PA 95-022)

Under this program, NIDA is encouraging research on how drug abuse treatment services and other health services affect the prevention and management of HIV infection and AIDS in drug-abusing populations. Of special interest are proposals that focus on how financing, organization, and management affect those services for people who are either at high risk of becoming HIV positive or are HIV positive.

For further information, contact Dr. Frank M. Tims, NIDA, 6001 Executive Blvd, Bethesda, Maryland 20892 , (301) 443-4060. Internet: ftims@aoada.ssw.dhhs.gov

Strategies to Reduce HIV Sexual Risk Practices in Drug Users (PA 94-054)

This NIDA program announcement seeks innovative interventions aimed at reducing or eliminating high-risk sexual practices among injecting drug users or crack smokers. The research will proceed in two phases. The first will assess behaviors and develop interventions; the second will implement and evaluate the interventions.

For further information, contact Dr. Richard Needle, NIDA, 6001 Executive Blvd, Bethesda, Maryland 20892 , (301) 443-6720. Internet:rneedle@aoada.ssw.dhhs.gov

HIV-Related Therapeutics in Drug Users (PA-94-023)

Additional research on HIV-and AIDS-related treatment issues is needed to improve the clinical management of HIV-positive drug abusers. To meet this need, NIDA, in collaboration with the National Institute of Allergy and Infectious Diseases, is seeking research on behavioral, clinical, and pharmacological aspects of HIV-related therapeutics in drug users.

For further information, contact Katherine Davenny, NIDA, 6001 Executive Blvd, Bethesda, Maryland 20892 , (301) 443-1801. Internet:kdavenny@aoada.ssw.dhhs.gov

Research on Needle Hygiene and Needle Exchange Programs (PA-94-010)

Under this program, NIDA is interested in studies that will extend ongoing research in areas such as needle-sharing practices, use of needle exchange, and evaluation of needle hygiene and needle-exchange interventions as part of HIV prevention programs.

For further information, contact Dr. Richard Needle, NIDA, 6001 Executive Blvd, Bethesda, Maryland 20892 , (301) 443-6720. Internet:rneedle@aoada.ssw.dhhs.gov

Partner Notification to HIV-Infected Drug Users (PA-93-111)

This announcement encourages studies to evaluate and implement strategies to reach HIV-positive drug users and motivate them to disclose their infection to sexual and needle-sharing partners.

For further information, contact Dr. Richard Needle, NIDA, 6001 Executive Blvd, Bethesda, Maryland 20892 , (301) 443-6720 Internet:rneedle@aoada.ssw.dhhs.gov

Health Care Services for Persons with HIV Infection (PA-93-110)

The continued growth of the HIV epidemic has created an urgent need to better understand the public policy implications of providing care for individuals with HIV. In cooperation with other Federal agencies, NIDA is looking for short-term research to find better ways to inform public policymakers about the delivery of health care services to people with HIV-related diseases.

For further information, contact Dr. Harry Haverkos, NIDA, 6001 Executive Blvd, Bethesda, Maryland 20892 , (301) 443-6046. Internet:hhaverko@aoada.ssw.dhhs.gov

Drug Abuse Aspects of AIDS (PA-93-098)

This program announcement encourages research on the relationships between drug abuse and associated behaviors and HIV infection and its progression to AIDS. It emphasizes areas of study such as treatment of drug dependence, prevention strategies, risk behaviors, etiology and pathogenesis, and clinical issues.

For further information, contact Dr. Harry Haverkos, NIDA, 6001 Executive Blvd, Bethesda, Maryland 20892 , (301) 443-6046. Internet:hhaverko@aoada.ssw.dhhs.gov

Including AIDS Research in Behavioral Therapies Development Program (PA-94-078)

Addendum

This announcement supplements NIDA's Behavioral Therapies Development Program Announcement (PA-94-078). It calls for studies that make HIV risk reduction strategies an integral component of behavioral therapies including counseling, psychotherapy, behavioral therapy, and skills training for drug abuse and dependence.

For further information, contact Debra Grossman, NIDA, 6001 Executive Blvd, Bethesda, Maryland 20892 , (301) 443-0107. Internet: dgrossma@aoada.ssw.dhhs.gov

The Spread of Tuberculosis Among Drug Users (PA-93-44)

Drug users, especially those whose immune systems are compromised by HIV infection, constitute one of the high-risk categories for tuberculosis. Under this program, NIDA seeks research that will help control the spread of tuberculosis among drug users.

For further information, contact Katherine Davenny, NIDA, 6001 Executive Blvd, Bethesda, Maryland 20892 , (301) 443-1801. Internet: kdavenny@aoada.ssw.dhhs.gov

Children with HIV Infection and AIDS (PA-90-15)

NIDA, in conjunction with other NIH agencies, is seeking research on all aspects of HIV and AIDS in children. Studies should strive to provide a better understanding of the prevalence of HIV and AIDS in children and a better description of the disease process.

For further information, contact Dr. Vincent Smeriglio, NIDA, 6001 Executive Blvd, Bethesda, Maryland 20892 , (301) 443-1801. Internet: vsmerigl@aoada.ssw.dhhs.gov

From NIDA NOTES, May/June, 1995

Archive Home | Accessibility | Privacy | FOIA (NIH) | Current NIDA Home Page _ The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? See our Contact Information. .